Lacosamide vs Zonisamide (Zonegran)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline

Lacosamide · Vimpat

Marketed by UCB

Approved in Epilepsysmall molecule
Reliable signal

NCT00136019 · Phase 3 · completed

Multicentre, double-blind, placebo-controlled trial (SP754): 405 patients randomised 1:2:1 to placebo, lacosamide 400 mg or 600 mg/day; the prespecified primary outcome was met. The registry record omits the arms; the design is from the publication.

The old registry record lists only the lacosamide intervention; the design and arms are from the publication.

Reported efficacy

Efficacy is evaluated based on reduction in seizure frequency, 50 percent reduction in seizures, number and percentage of seizure-free days, and achievement of seizure-free status.: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). (met)

Result source: NCT00136019

Zonisamide (Zonegran)

Marketed by Advanz Pharma and partners

Approved in Epilepsysmall molecule
Weak signal

NCT00056576 · Phase 3 · completed

Although 165 participants were reportedly randomized and treatment was double-blinded, the study is listed as a single-group design with no placebo or active comparator. No primary endpoint or results are posted, so whether the primary outcome was met or missed cannot be assessed.

Reported efficacy

Percentage of Participants Remaining in the Study at Each Visit (At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months): Long-term extension; the registered primary was retention in the study at each visit, with no formal test. Retention at 12 months: zonisamide 58.4% (n=137) vs carbamazepine 61.4% (n=158) (CT.gov posted results). (not_applicable)

Result source: NCT00848549

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLacosamideZonisamide (Zonegran)
Seizure frequency, % change—Not posted · NCT00136019-48.4% vs -26.6%−21.8 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • -32.7% vs -35.6% wk 16 · n 24 · Phase 3 · primary NCT00292461
50% responder rate—Not posted · NCT0013601948.6% vs 34.9%+13.7 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • 45.8% vs 45.8% wk 16 · n 24 · Phase 3 · secondary NCT00292461
Seizure freedom—Not posted · NCT001360191.8% vs 2.8%−1 vs placebo100 mg · wk 16 · n 111NCT00327717

Seizure frequency, % change

Lacosamide
—Not posted · NCT00136019
Zonisamide (Zonegran)
-48.4% vs -26.6%−21.8 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • -32.7% vs -35.6% wk 16 · n 24 · Phase 3 · primary NCT00292461

50% responder rate

Lacosamide
—Not posted · NCT00136019
Zonisamide (Zonegran)
48.6% vs 34.9%+13.7 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • 45.8% vs 45.8% wk 16 · n 24 · Phase 3 · secondary NCT00292461

Seizure freedom

Lacosamide
—Not posted · NCT00136019
Zonisamide (Zonegran)
1.8% vs 2.8%−1 vs placebo100 mg · wk 16 · n 111NCT00327717
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Lacosamide: 10 of 10 rows · Zonisamide (Zonegran): 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLacosamide
Rows use multiple source trials
Zonisamide (Zonegran)
Rows use multiple source trials
Partial Onset Seizure Frequency
percent change · % of baseline
No placebo or comparator arm
-44.47% (n=471) @ 323wka,b,c,d
NCT01832038 · Phase 3 · registry result, not featured evidence
1 other source trial
-24.13% (n=308)
NCT00938912 · Phase 2 · registry result, not featured evidence
-16.35% (n=102) @ 16wka,b,c,d
NCT01140867 · Phase 4 · registry result, not featured evidence
Seizure 50
responder rate · % of participants
Maintenance
49.2% (n=179) vs 19.7% (n=183) placebo @ 24wk*400 mg/daye,f,c,g
NCT01710657 · Phase 3 · registry result, not featured evidence · converted to % from 88 participants as posted
show 1 more dose
38.5% (n=182) vs 19.7% (n=183) placebo @ 24wk*200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence · converted to % from 70 participants as posted
50% (n=107) vs 31% (n=100) placebo @ 20wkf,c,g
NCT00566254 · Phase 3 · registry result, not featured evidence
Seizure 50
responder rate · % of participants
No placebo or comparator arm
57.1% (n=471) @ 323wka,b,c,d
NCT01832038 · Phase 3 · registry result, not featured evidence
3 other source trials
50% (n=376)
NCT00515619 · Phase 3 · registry result, not featured evidence
48.2% (n=307)
NCT00522275 · Phase 3 · registry result, not featured evidence
51.2% (n=369)
NCT00552305 · Phase 2 · registry result, not featured evidence
61.76% (n=102) @ 16wka,b,c,d
NCT01140867 · Phase 4 · registry result, not featured evidence
Seizure-free
absolute value · months
3.88 vs 3.75 Levetiracetam months @ 26wk*f,c,h
NCT01345058 · Phase 3 · registry result, not featured evidence · combination · converted to months from 118.11 days as posted
0.73 vs 0.7 placebo months @ 12wk*100 mgf,c,h
NCT00327717 · Phase 3 · registry result, not featured evidence · converted to months from 22.31 days as posted
Seizure-free
responder rate · % of participants
No placebo or comparator arm
7.4% (n=323)i,f,c,j
NCT00938912 · Phase 2 · registry result, not featured evidence
57.6% (n=41) @ 24wkhigh dosee,i,f,c,j
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more dose
63.1% (n=49) @ 24wklow dose
NCT01127165 · Phase 4 · registry result, not featured evidence
Time to First Seizure
time to event · months
5.32 vs 3.83 Levetiracetam months*f,c,j
NCT01345058 · Phase 3 · registry result, not featured evidence · combination · converted to months from 162 days as posted
0.73 vs 0.7 placebo months*100 mgf,c,j
NCT00327717 · Phase 3 · registry result, not featured evidence · converted to months from 22.31 days as posted
Dropout rate
34.3%k
NCT02408549 · Phase 3 · combination
show 45 more results
—Lacosamide (SS) Safety Follow-up P
NCT02408523 · Phase 3
—Lacosamide (SS) Taper Period
NCT02408523 · Phase 3
—Lacosamide (SS) Transition Period
NCT02408523 · Phase 3
—Lacosamide (SS) Treatment Period
NCT02408523 · Phase 3
7.1%
NCT01190098 · Phase 4 · registry result, not featured evidence
16.7%First Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
18.3%Later Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
36.8%Lacosamide: >=2 to <4 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
13.8%Lacosamide: >=4 to <6 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
26.9%
NCT01964560 · Phase 3 · registry result, not featured evidence
—
NCT02477839 · Phase 3 · registry result, not featured evidence
—
NCT02582866 · Phase 3 · registry result, not featured evidence
—
NCT01832038 · Phase 3 · registry result, not featured evidence
36.8%
NCT02124564 · Phase 3 · registry result, not featured evidence
11.7%
NCT01921205 · Phase 3 · registry result, not featured evidence
24.4%Lacosamide
NCT01465997 · Phase 3 · registry result, not featured evidence
—Lacosamide (SS)
NCT01465997 · Phase 3 · registry result, not featured evidence
40.1%
NCT01243177 · Phase 3 · registry result, not featured evidence
34.8%
NCT00530855 · Phase 3 · registry result, not featured evidence
0%
NCT02192814 · Phase 3 · registry result, not featured evidence
25%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
17.8%400 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
6.6%200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
22.5%
NCT01484977 · Phase 3 · registry result, not featured evidence
39.2%400 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
34.9%300 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
57.4%
NCT00515619 · Phase 3 · registry result, not featured evidence
28.9%
NCT00655486 · Phase 3 · registry result, not featured evidence
55.2%
NCT00522275 · Phase 3 · registry result, not featured evidence
16%400 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
6%300 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 1 Month -
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 8 - < 17 Y
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—
NCT00938912 · Phase 2 · registry result, not featured evidence
10%Lacosamide 1 Month - <4 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
33.3%Lacosamide 12 Years - <18 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
12.5%Lacosamide 4 Years - <12 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
40%>=1 Month to <4 Years (Safety Set)
NCT00938431 · Phase 2 · registry result, not featured evidence
88.9%>=12 Years to <=17 Years (Safety S
NCT00938431 · Phase 2 · registry result, not featured evidence
39.1%>=4 Years to <12 Years (Safety Set
NCT00938431 · Phase 2 · registry result, not featured evidence
25.6%
NCT01118962 · Phase 2 · registry result, not featured evidence
18.4%
NCT01118949 · Phase 2 · registry result, not featured evidence
67.6%
NCT00552305 · Phase 2 · registry result, not featured evidence
42.9%Zonisamidek
NCT00848549 · Phase 3 · monotherapy
show 12 more results
—Zonisamide (Base Study 310, NCT004
NCT00848549 · Phase 3 · monotherapy
—Zonisamide (Extension Study 314, N
NCT00848549 · Phase 3 · monotherapy
27.3%
NCT01140867 · Phase 4 · registry result, not featured evidence
31.7%high dose
NCT01127165 · Phase 4 · registry result, not featured evidence
24.6%low dose
NCT01127165 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
29.2%Zonisamide (Zonisamide During Core
NCT01136954 · Phase 3 · registry result, not featured evidence
33.3%Zonisamide(Placebo During Core Stu
NCT01136954 · Phase 3 · registry result, not featured evidence
13.1%
NCT00566254 · Phase 3 · registry result, not featured evidence
42.9%
NCT00477295 · Phase 3 · registry result, not featured evidence
29.4%
NCT00292461 · Phase 3 · registry result, not featured evidence
7.5%100 mg
NCT00327717 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
6.3%k
NCT02408549 · Phase 3 · combination
show 45 more results
—Lacosamide (SS) Safety Follow-up P
NCT02408523 · Phase 3
—Lacosamide (SS) Taper Period
NCT02408523 · Phase 3
—Lacosamide (SS) Transition Period
NCT02408523 · Phase 3
—Lacosamide (SS) Treatment Period
NCT02408523 · Phase 3
4.8%
NCT01190098 · Phase 4 · registry result, not featured evidence
9.4%First Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
12.8%Later Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
0%Lacosamide: >=2 to <4 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
6.9%Lacosamide: >=4 to <6 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
4.3%
NCT01964560 · Phase 3 · registry result, not featured evidence
—
NCT02477839 · Phase 3 · registry result, not featured evidence
—
NCT02582866 · Phase 3 · registry result, not featured evidence
—
NCT01832038 · Phase 3 · registry result, not featured evidence
10.5%
NCT02124564 · Phase 3 · registry result, not featured evidence
4.1%
NCT01921205 · Phase 3 · registry result, not featured evidence
4.3%Lacosamide
NCT01465997 · Phase 3 · registry result, not featured evidence
—Lacosamide (SS)
NCT01465997 · Phase 3 · registry result, not featured evidence
—
NCT01243177 · Phase 3 · registry result, not featured evidence
—
NCT00530855 · Phase 3 · registry result, not featured evidence
—
NCT02192814 · Phase 3 · registry result, not featured evidence
—
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
15.6%400 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
4.4%200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
6.7%
NCT01484977 · Phase 3 · registry result, not featured evidence
17.6%400 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
15.1%300 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
9%
NCT00515619 · Phase 3 · registry result, not featured evidence
10.3%
NCT00655486 · Phase 3 · registry result, not featured evidence
11.4%
NCT00522275 · Phase 3 · registry result, not featured evidence
16%400 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
6%300 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 1 Month -
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—Lacosamide Age Cohort ≥ 8 - < 17 Y
NCT02710890 · Phase 2/3 · registry result, not featured evidence
—
NCT00938912 · Phase 2 · registry result, not featured evidence
0%Lacosamide 1 Month - <4 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
14.3%Lacosamide 12 Years - <18 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
0%Lacosamide 4 Years - <12 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
33.3%>=1 Month to <4 Years (Safety Set)
NCT00938431 · Phase 2 · registry result, not featured evidence
66.7%>=12 Years to <=17 Years (Safety S
NCT00938431 · Phase 2 · registry result, not featured evidence
34.8%>=4 Years to <12 Years (Safety Set
NCT00938431 · Phase 2 · registry result, not featured evidence
5.1%
NCT01118962 · Phase 2 · registry result, not featured evidence
10.2%
NCT01118949 · Phase 2 · registry result, not featured evidence
13%
NCT00552305 · Phase 2 · registry result, not featured evidence
11%Zonisamidek
NCT00848549 · Phase 3 · monotherapy
show 12 more results
—Zonisamide (Base Study 310, NCT004
NCT00848549 · Phase 3 · monotherapy
—Zonisamide (Extension Study 314, N
NCT00848549 · Phase 3 · monotherapy
18.2%
NCT01140867 · Phase 4 · registry result, not featured evidence
3.3%high dose
NCT01127165 · Phase 4 · registry result, not featured evidence
3.1%low dose
NCT01127165 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
2.8%Zonisamide (Zonisamide During Core
NCT01136954 · Phase 3 · registry result, not featured evidence
4.2%Zonisamide(Placebo During Core Stu
NCT01136954 · Phase 3 · registry result, not featured evidence
0.9%
NCT00566254 · Phase 3 · registry result, not featured evidence
11%
NCT00477295 · Phase 3 · registry result, not featured evidence
11.8%
NCT00292461 · Phase 3 · registry result, not featured evidence
5%100 mg
NCT00327717 · Phase 3 · registry result, not featured evidence
Serious AEs
22.6%k
NCT02408549 · Phase 3 · combination
show 45 more results
9.1%Lacosamide (SS) Safety Follow-up P
NCT02408523 · Phase 3
0%Lacosamide (SS) Taper Period
NCT02408523 · Phase 3
3%Lacosamide (SS) Transition Period
NCT02408523 · Phase 3
6.6%Lacosamide (SS) Treatment Period
NCT02408523 · Phase 3
7.1%
NCT01190098 · Phase 4 · registry result, not featured evidence
8.3%First Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
5.3%Later Add-on
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
10.5%Lacosamide: >=2 to <4 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
17.2%Lacosamide: >=4 to <6 Years
NCT04627285 · Phase 3 · registry result, not featured evidence
20.6%
NCT01964560 · Phase 3 · registry result, not featured evidence
4.7%
NCT02477839 · Phase 3 · registry result, not featured evidence
14.2%
NCT02582866 · Phase 3 · registry result, not featured evidence
17.5%
NCT01832038 · Phase 3 · registry result, not featured evidence
10.5%
NCT02124564 · Phase 3 · registry result, not featured evidence
6.4%
NCT01921205 · Phase 3 · registry result, not featured evidence
—Lacosamide
NCT01465997 · Phase 3 · registry result, not featured evidence
11.5%Lacosamide (SS)
NCT01465997 · Phase 3 · registry result, not featured evidence
8.1%
NCT01243177 · Phase 3 · registry result, not featured evidence
17.4%
NCT00530855 · Phase 3 · registry result, not featured evidence
0%
NCT02192814 · Phase 3 · registry result, not featured evidence
0%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
5%400 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
1.1%200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
6.7%
NCT01484977 · Phase 3 · registry result, not featured evidence
6.6%400 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
3.8%300 mg/day
NCT00520741 · Phase 3 · registry result, not featured evidence
23.1%
NCT00515619 · Phase 3 · registry result, not featured evidence
10.3%
NCT00655486 · Phase 3 · registry result, not featured evidence
23.1%
NCT00522275 · Phase 3 · registry result, not featured evidence
4%400 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT00655551 · Phase 3 · registry result, not featured evidence
0%Lacosamide Age Cohort ≥ 1 Month -
NCT02710890 · Phase 2/3 · registry result, not featured evidence
0%Lacosamide Age Cohort ≥ 8 - < 17 Y
NCT02710890 · Phase 2/3 · registry result, not featured evidence
22.5%
NCT00938912 · Phase 2 · registry result, not featured evidence
0%Lacosamide 1 Month - <4 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
4.8%Lacosamide 12 Years - <18 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
0%Lacosamide 4 Years - <12 Years
NCT01969851 · Phase 2 · registry result, not featured evidence
22.2%400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
20%>=1 Month to <4 Years (Safety Set)
NCT00938431 · Phase 2 · registry result, not featured evidence
0%>=12 Years to <=17 Years (Safety S
NCT00938431 · Phase 2 · registry result, not featured evidence
13%>=4 Years to <12 Years (Safety Set
NCT00938431 · Phase 2 · registry result, not featured evidence
7.7%
NCT01118962 · Phase 2 · registry result, not featured evidence
2%
NCT01118949 · Phase 2 · registry result, not featured evidence
33.8%
NCT00552305 · Phase 2 · registry result, not featured evidence
—Zonisamidek
NCT00848549 · Phase 3 · monotherapy
show 12 more results
5.3%Zonisamide (Base Study 310, NCT004
NCT00848549 · Phase 3 · monotherapy
5.1%Zonisamide (Extension Study 314, N
NCT00848549 · Phase 3 · monotherapy
1.7%
NCT01140867 · Phase 4 · registry result, not featured evidence
1.7%high dose
NCT01127165 · Phase 4 · registry result, not featured evidence
3.1%low dose
NCT01127165 · Phase 4 · registry result, not featured evidence
0%
NCT00855738 · Phase 4 · registry result, not featured evidence
9.7%Zonisamide (Zonisamide During Core
NCT01136954 · Phase 3 · registry result, not featured evidence
4.2%Zonisamide(Placebo During Core Stu
NCT01136954 · Phase 3 · registry result, not featured evidence
3.7%
NCT00566254 · Phase 3 · registry result, not featured evidence
5.3%
NCT00477295 · Phase 3 · registry result, not featured evidence
0%
NCT00292461 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT00327717 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
k
headache 23.4%
dizziness 22.2%
nasopharyngitis 21.8%
NCT02408549 · Phase 3 · combination
show 44 more results
dizziness 0% (placebo 0%)
drooling 0% (placebo 0%)
dyspepsia 0% (placebo 0%)
NCT02408523 · Phase 3
drooling 11.1% (placebo 0%)
grand mal convulsion 11.1% (placebo 0%)
laceration 11.1% (placebo 0%)
NCT02408523 · Phase 3
dizziness 3% (placebo 0%)
nasopharyngitis 1% (placebo 0%)
vertigo 1% (placebo 0%)
NCT02408523 · Phase 3
dizziness 21.5% (placebo 0%)
somnolence 14.9% (placebo 0%)
headache 13.2% (placebo 0%)
NCT02408523 · Phase 3
dizziness 42.9% (placebo 30%)
headache 40.5% (placebo 40%)
common cold/flu 21.4% (placebo 10%)
NCT01190098 · Phase 4 · registry result, not featured evidence
dizziness 31.3%
headache 13.5%
vertigo 9.4%
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
dizziness 33.1%
somnolence 15%
headache 11.4%
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
upper respiratory tract infection 26.3%
NCT04627285 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 13.8%
NCT04627285 · Phase 3 · registry result, not featured evidence
pyrexia 15.9%
upper respiratory tract infection 15.4%
nasopharyngitis 10.6%
NCT01964560 · Phase 3 · registry result, not featured evidence
somnolence 14.1% (placebo 3.9%)
irritability 5.5% (placebo 4.7%)
pyrexia 5.5% (placebo 11.8%)
NCT02477839 · Phase 3 · registry result, not featured evidence
headache 10.4%
nasopharyngitis 7.5%
NCT02582866 · Phase 3 · registry result, not featured evidence
nasopharyngitis 33%
dizziness 26.4%
upper respiratory tract infection 20.9%
NCT01832038 · Phase 3 · registry result, not featured evidence
dizziness 52.6%
somnolence 42.1%
nasopharyngitis 36.8%
NCT02124564 · Phase 3 · registry result, not featured evidence
somnolence 16.4% (placebo 6.4%)
nasopharyngitis 11.7% (placebo 5.8%)
dizziness 10.5% (placebo 7.6%)
NCT01921205 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.2%
headache 6.1%
dizziness 4.3%
NCT01465997 · Phase 3 · registry result, not featured evidence
headache 13.5%
dizziness 11.9%
fatigue 7.7%
NCT01243177 · Phase 3 · registry result, not featured evidence
dizziness 27.6%
headache 17.1%
nausea 14.3%
NCT00530855 · Phase 3 · registry result, not featured evidence
abdominal pain upper 11.1%
injection site erythema 11.1%
injection site pain 11.1%
NCT02192814 · Phase 3 · registry result, not featured evidence
erectile dysfunction 11.1%
fatigue 11.1%
memory/cognitive difficulties/confusion 11.1%
NCT01345058 · Phase 3 · registry result, not featured evidence · combination
400 mg/day
dizziness 35% (placebo 13%)
nasopharyngitis 16.1% (placebo 13%)
headache 10.6% (placebo 6%)
NCT01710657 · Phase 3 · registry result, not featured evidence
200 mg/day
dizziness 18% (placebo 13%)
nasopharyngitis 15.3% (placebo 13%)
somnolence 9.8% (placebo 4.9%)
NCT01710657 · Phase 3 · registry result, not featured evidence
dizziness 23.3%
headache 15%
fatigue 8.3%
NCT01484977 · Phase 3 · registry result, not featured evidence
400 mg/day
dizziness 27%
nausea 14.4%
headache 14.1%
NCT00520741 · Phase 3 · registry result, not featured evidence
300 mg/day
headache 19.8%
dizziness 17.9%
convulsion 16%
NCT00520741 · Phase 3 · registry result, not featured evidence
dizziness 24.2%
headache 14.4%
nasopharyngitis 13.8%
NCT00515619 · Phase 3 · registry result, not featured evidence
dizziness 44.3%
diplopia 17.5%
vomiting 16.5%
NCT00655486 · Phase 3 · registry result, not featured evidence
dizziness 50%
headache 21.8%
contusion 18.5%
NCT00522275 · Phase 3 · registry result, not featured evidence
400 mg
dizziness 60%
somnolence 36%
nausea 24%
NCT00655551 · Phase 3 · registry result, not featured evidence
300 mg
dizziness 46%
somnolence 34%
fatigue 18%
NCT00655551 · Phase 3 · registry result, not featured evidence
200 mg
dizziness 20%
gait disturbance 8%
headache 8%
NCT00655551 · Phase 3 · registry result, not featured evidence
functional gastrointestinal disorder 2.1%
pyrexia 2.1%
respiratory tract infection 2.1%
NCT02710890 · Phase 2/3 · registry result, not featured evidence
blood triglycerides increased 3.6%
blood cholesterol increased 1.8%
functional gastrointestinal disorder 0%
NCT02710890 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 24.9%
upper respiratory tract infection 23.6%
pyrexia 21.9%
NCT00938912 · Phase 2 · registry result, not featured evidence
nasopharyngitis 50%
pyrexia 40%
somnolence 40%
NCT01969851 · Phase 2 · registry result, not featured evidence
headache 19%
nasopharyngitis 14.3%
pharyngotonsillitis 14.3%
NCT01969851 · Phase 2 · registry result, not featured evidence
pyrexia 25%
cough 16.7%
upper respiratory tract infection 16.7%
NCT01969851 · Phase 2 · registry result, not featured evidence
400mg
respiratory failure 6.7%
acute respiratory failure 4.4%
bradycardia 4.4%
NCT01458522 · Phase 2 · registry result, not featured evidence
irritability 20%
pharyngotonsillitis 20%
diarrhoea 13.3%
NCT00938431 · Phase 2 · registry result, not featured evidence
balance disorder 22.2%
dizziness 22.2%
rash 22.2%
NCT00938431 · Phase 2 · registry result, not featured evidence
vomiting 30.4%
diarrhoea 17.4%
dizziness 13%
NCT00938431 · Phase 2 · registry result, not featured evidence
dizziness 25.6%
upper respiratory tract infection 25.6%
headache 17.9%
NCT01118962 · Phase 2 · registry result, not featured evidence
dizziness 38.8%
nausea 26.5%
headache 16.3%
NCT01118949 · Phase 2 · registry result, not featured evidence
dizziness 39.7%
headache 20.8%
nausea 17.3%
NCT00552305 · Phase 2 · registry result, not featured evidence
k
headache 10.3%
decreased appetite 7.8%
weight decreased 6.8%
NCT00848549 · Phase 3 · monotherapy
show 11 more results
weight decreased 5.8%
headache 4.4%
decreased appetite 0%
NCT00848549 · Phase 3 · monotherapy
dizziness 28.1%
somnolence 24%
anorexia 18.2%
NCT01140867 · Phase 4 · registry result, not featured evidence
high dose
dizziness 5%
micturition disorder 5%
somnolence 5%
NCT01127165 · Phase 4 · registry result, not featured evidence
low dose
anorexia 4.6%
fatigue 3.1%
somnolence 3.1%
NCT01127165 · Phase 4 · registry result, not featured evidence
somnolence 7.5%
weight increased 5%
dizziness 2.5%
NCT00855738 · Phase 4 · registry result, not featured evidence
nasopharyngitis 12.5%
headache 9.7%
weight decreased 8.3%
NCT01136954 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.3%
weight decreased 8.3%
decreased appetite 6.9%
NCT01136954 · Phase 3 · registry result, not featured evidence
decreased appetite 6.5% (placebo 4%)
headache 6.5% (placebo 7%)
nasopharyngitis 5.6% (placebo 9%)
NCT00566254 · Phase 3 · registry result, not featured evidence
headache 10.3%
decreased appetite 7.8%
weight decreased 6.8%
NCT00477295 · Phase 3 · registry result, not featured evidence
hepatic enzyme abnormal 8.8%
blood alkaline phosphatase increased 5.9%
dizziness 5.9%
NCT00292461 · Phase 3 · registry result, not featured evidence
100 mg
anorexia 18.3% (placebo 5.1%)
somnolence 12.5% (placebo 14.4%)
headache 10.8% (placebo 5.1%)
NCT00327717 · Phase 3 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 323 weeks versus 16 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gAssessment timepoints differ: 24 weeks versus 20 weeks.
  8. hAssessment timepoints differ: 26 weeks versus 12 weeks.
  9. iTrial phases differ: Phase 2 versus Phase 4.
  10. jThe assessment timepoint is not available for both results.
  11. kPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lacosamide

Convulsive Seizure Frequency -88.58% (n=238)
percent change · % of baseline
No placebo or comparator arm
NCT02408549 · Phase 3 · combination
Time to Second PGTC Seizure 49 vs 76 placebo count @ 24wk
event count · count
NCT02408523 · Phase 3
PGTC Seizure Free 31% (n=118) vs 17.3% (n=121) placebo @ 24wk
responder rate · % of participants
NCT02408523 · Phase 3
Time to First PGTC Seizure 79 vs 97 placebo count @ 24wk
event count · count
NCT02408523 · Phase 3
ESS -1.2 vs -1.1 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
FSS 0.3 vs -5.4 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
PSQI -1.6 vs -1.3 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
PHQ-9 -1.1 vs -1.2 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
QOLIE-31-P 4 vs 4.2 placebo score
absolute change · score
NCT01190098 · Phase 4 · registry result, not featured evidence
Seizure-free 37.5% (n=72) @ 18wk
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
show 1 more result
14.9% (n=261) @ 18wk
NCT00955357 · Phase 4 · registry result, not featured evidence · add on
Seizure-free 66.96 % of time
absolute value · % of time
No placebo or comparator arm
NCT01964560 · Phase 3 · registry result, not featured evidence
Partial Onset Seizure Frequency -48.78% (n=179) vs -10.1% (n=183) placebo @ 24wk400 mg/day
percent change · % of baseline
Maintenance
NCT01710657 · Phase 3 · registry result, not featured evidence
show 3 more results
-36.75% (n=182) vs -10.1% (n=183) placebo @ 24wk200 mg/day
NCT01710657 · Phase 3 · registry result, not featured evidence
1.4% (n=116) vs 1.44% (n=120) placebo @ 4wk
NCT02477839 · Phase 3 · registry result, not featured evidence
-32.3564% (n=121) vs -26.7927% (n=122) placebo @ 4wk
NCT02477839 · Phase 3 · registry result, not featured evidence

+ 19 further endpoints in the CSV export.

Zonisamide (Zonegran)

Seizure Free 24 32.3% (n=281) vs 35.2% (n=300) Carbamazepine @ 117wk
responder rate · % of participants
Extension (open-label)
NCT00848549 · Phase 3 · monotherapy
QOLIE-31-P 4.697 vs 7.101 Carbamazepine score @ 0wk
absolute change · score
NCT00848549 · Phase 3 · monotherapy
show 4 more results
6.101 vs 10.956 Carbamazepine score @ 26wk
NCT00848549 · Phase 3 · monotherapy
8.602 vs 11.687 Carbamazepine score @ 52wk
NCT00848549 · Phase 3 · monotherapy
4.287 vs 1.902 Carbamazepine score @ 78wk
NCT00848549 · Phase 3 · monotherapy
-0.292 vs 15.849 Carbamazepine score @ 117wk
NCT00848549 · Phase 3 · monotherapy
Kwisc III -1.3913 score @ 24wklow dose
absolute change · score
No placebo or comparator arm
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more result
0.1071 score @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
Kcbc -5.259 score @ 24wklow dose
absolute change · score
No placebo or comparator arm
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more result
-1.611 score @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
K-QOLCE 4.7931 score @ 24wklow dose
absolute change · score
No placebo or comparator arm
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more result
1.2286 score @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
Seizure 50 55.6% (n=72) @ 59wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01136954 · Phase 3 · registry result, not featured evidence
show 1 more result
56.9% (n=72) @ 59wk
NCT01136954 · Phase 3 · registry result, not featured evidence
Seizure Frequency -3.8 Seizures @ 59wk
absolute change · Seizures
Extension (open-label)
No placebo or comparator arm
NCT01136954 · Phase 3 · registry result, not featured evidence
show 1 more result
-4.7 Seizures @ 59wk
NCT01136954 · Phase 3 · registry result, not featured evidence
Seizure Frequency -64.6% (n=72) @ 59wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT01136954 · Phase 3 · registry result, not featured evidence
show 1 more result
-67.9% (n=72) @ 59wk
NCT01136954 · Phase 3 · registry result, not featured evidence
Seizure Frequency -50% (n=107) vs -24.5% (n=100) placebo @ 20wk
percent change · % of baseline
Maintenance
NCT00566254 · Phase 3 · registry result, not featured evidence
Seizure Free 26 79.4% (n=223) vs 83.7% (n=233) Carbamazepine
responder rate · % of participants
Maintenance
NCT00477295 · Phase 3 · registry result, not featured evidence
Seizure Free 12 67.6% (n=216) vs 74.7% (n=229) Carbamazepine
responder rate · % of participants
Maintenance
NCT00477295 · Phase 3 · registry result, not featured evidence
Time to Treatment Failure 23.72 vs NA Carbamazepine months
time to event · months
NCT00477295 · Phase 3 · registry result, not featured evidence · converted to months from 722 days as posted

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lacosamide's landscape · Zonisamide (Zonegran)'s landscape